Artiva Biotherapeutics (NASDAQ:ARTV) Rating Increased to Buy at HC Wainwright

Artiva Biotherapeutics (NASDAQ:ARTV) was upgraded by equities researchers at HC Wainwright to a “buy” rating in a research note issued to investors on Wednesday, Marketbeat Ratings reports. The firm presently has a $12.00 price target on the stock. HC Wainwright’s target price points to a potential upside of 485.37% from the stock’s current price.

A number of other equities research analysts also recently weighed in on the stock. Cantor Fitzgerald reduced their price target on shares of Artiva Biotherapeutics from $23.00 to $20.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 25th. Needham & Company LLC lowered their price objective on shares of Artiva Biotherapeutics from $23.00 to $18.00 and set a “buy” rating for the company in a research report on Thursday, May 15th. Finally, Wedbush restated an “outperform” rating and issued a $18.00 target price on shares of Artiva Biotherapeutics in a research report on Tuesday, March 25th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $17.80.

Artiva Biotherapeutics Trading Up 4.6%

Shares of ARTV opened at $2.05 on Wednesday. Artiva Biotherapeutics has a 52-week low of $1.78 and a 52-week high of $17.31. The business’s fifty day moving average is $2.14 and its 200-day moving average is $5.38.

Artiva Biotherapeutics (NASDAQ:ARTV) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.15). Research analysts forecast that Artiva Biotherapeutics will post -4.95 earnings per share for the current year.

Institutional Trading of Artiva Biotherapeutics

A number of hedge funds have recently made changes to their positions in the company. Wells Fargo & Company MN grew its holdings in shares of Artiva Biotherapeutics by 64.0% during the fourth quarter. Wells Fargo & Company MN now owns 8,616 shares of the company’s stock worth $87,000 after purchasing an additional 3,361 shares during the last quarter. BNP Paribas Financial Markets raised its holdings in Artiva Biotherapeutics by 262.1% in the 4th quarter. BNP Paribas Financial Markets now owns 9,879 shares of the company’s stock valued at $100,000 after buying an additional 7,151 shares during the last quarter. Nuveen LLC acquired a new stake in Artiva Biotherapeutics during the 1st quarter worth approximately $144,000. Charles Schwab Investment Management Inc. grew its holdings in Artiva Biotherapeutics by 26.1% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 54,881 shares of the company’s stock worth $165,000 after acquiring an additional 11,355 shares during the last quarter. Finally, Deutsche Bank AG bought a new stake in Artiva Biotherapeutics during the 4th quarter worth approximately $216,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.